Skip to main content

Drug Safety

      My favorite three presentations from day 4 at ACR 2021 included the following: Breakthrough Infections in Rheumatic Disease Patients Late-Breaking Abstract L16 - Dr. Jazvinder Singh presented the…
      RT @swethaann23: Retrospective chart review of rheumatic irAE patients:

      Persistent rheumatic irAE activity 🔼received
      3 years 1 month ago
      Retrospective chart review of rheumatic irAE patients: Persistent rheumatic irAE activity 🔼received GC Inflammatory arthritis pts 🔼risk of persistent rheumatic irAE Risk factors for mortality➡️tumor progression➕ continued Rx GC at last follow-up Abst#1516 #ACR21 @RheumNow https://t.co/KusNaVlEXp
      RT @AkhilSoodMD: Abst 1517
      Weinmann & colleagues studied prevalence of autoantibodies in Melanoma pts treated w/ ICI
      3 years 1 month ago
      Abst 1517 Weinmann & colleagues studied prevalence of autoantibodies in Melanoma pts treated w/ ICI & developed rheumatic IRAE - Most common rheumatic IRAE = inflammatory arthritis - Higher prevalence of ANA in those tx w/ chemo prior to ICI #ACR21 @RheumNow https://t.co/7qgogSMjUr
      Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: Secukinumab Efficacy in Enthesitis-Related and Juvenile Psoriatic Arthritis. Abstract 1424 – Dr. Hermine…
      Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions? The NOR-DRUM trials (A and B) are the first randomized trials to assess…
      ×